Nimesulide over 100 mg banned, cough syrup counter sale may stop, Pg5

Key Highlights:

• The government has banned the manufacture, sale, and distribution of nimesulide in oral immediate-release formulations above 100 mg due to health risks.
• The Ministry of Health and Family Welfare issued the notification, citing the availability of safer alternatives.
• A draft notification has been released to remove cough syrups from the list of over-the-counter medicines.
• The removal of cough syrups targets Schedule K, which lists medicines exempt from prescription requirements.

Detailed Insights:

• The ban on nimesulide aims to mitigate potential health risks associated with higher dosages of the medication.
• The decision to remove cough syrups from over-the-counter availability may lead to increased regulation and monitoring of their sale.
• Schedule K drugs are those exempted from needing a prescription from a registered medical practitioner, allowing them to be sold over the counter.
• This move could impact pharmaceutical companies and consumers, potentially requiring prescriptions for common cough remedies.

Key Concepts Involved:

• Nimesulide: A non-steroidal anti-inflammatory drug (NSAID) used to treat pain and fever.
• Over-the-counter medicines: Drugs that can be purchased without a prescription.
• Schedule K: A list of drugs exempt from prescription requirements under the Drugs and Cosmetics Rules.